IL106516A - Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate, the production of the same and pharmaceutical compositions containing it - Google Patents

Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate, the production of the same and pharmaceutical compositions containing it

Info

Publication number
IL106516A
IL106516A IL106516A IL10651693A IL106516A IL 106516 A IL106516 A IL 106516A IL 106516 A IL106516 A IL 106516A IL 10651693 A IL10651693 A IL 10651693A IL 106516 A IL106516 A IL 106516A
Authority
IL
Israel
Prior art keywords
hydrochloride
crystalline hydrate
crystalline
hydrate
water
Prior art date
Application number
IL106516A
Other languages
English (en)
Other versions
IL106516A0 (en
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of IL106516A0 publication Critical patent/IL106516A0/xx
Publication of IL106516A publication Critical patent/IL106516A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL106516A 1992-07-31 1993-07-28 Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate, the production of the same and pharmaceutical compositions containing it IL106516A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (2)

Publication Number Publication Date
IL106516A0 IL106516A0 (en) 1993-11-15
IL106516A true IL106516A (en) 1998-06-15

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
IL106516A IL106516A (en) 1992-07-31 1993-07-28 Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate, the production of the same and pharmaceutical compositions containing it

Country Status (23)

Country Link
US (1) US5407929A (pl)
EP (1) EP0581552B1 (pl)
KR (1) KR100245938B1 (pl)
CN (1) CN1037683C (pl)
AT (1) ATE165360T1 (pl)
AU (1) AU657866B2 (pl)
BR (1) BR9303235A (pl)
CA (1) CA2101502A1 (pl)
DE (1) DE69318077T2 (pl)
ES (1) ES2115725T3 (pl)
FI (1) FI933391A7 (pl)
GR (1) GR3026699T3 (pl)
HU (1) HU219637B (pl)
IL (1) IL106516A (pl)
MX (1) MX9304611A (pl)
NO (1) NO303734B1 (pl)
NZ (1) NZ248285A (pl)
PH (1) PH30109A (pl)
PL (2) PL172835B1 (pl)
RU (1) RU2118959C1 (pl)
TW (1) TW307769B (pl)
UA (1) UA37181C2 (pl)
ZA (1) ZA935529B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
WO2004072040A1 (en) 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
MXPA05010083A (es) 2003-03-27 2005-11-23 Basilea Pharmaceutica Ag Cefalosporina en forma cristalina.
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) * 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) * 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
KR100245938B1 (ko) 2000-04-01
FI933391L (fi) 1994-02-01
ZA935529B (en) 1994-02-24
HUT68602A (en) 1995-06-28
PL172835B1 (pl) 1997-12-31
EP0581552B1 (en) 1998-04-22
EP0581552A3 (en) 1994-06-01
TW307769B (pl) 1997-06-11
PL299870A1 (en) 1994-02-07
NO303734B1 (no) 1998-08-24
ATE165360T1 (de) 1998-05-15
RU2118959C1 (ru) 1998-09-20
HU9302194D0 (en) 1993-10-28
MX9304611A (es) 1994-02-28
EP0581552A2 (en) 1994-02-02
US5407929A (en) 1995-04-18
DE69318077T2 (de) 1998-10-29
NO932745D0 (no) 1993-07-30
FI933391A0 (fi) 1993-07-29
NZ248285A (en) 1994-07-26
AU657866B2 (en) 1995-03-23
AU4422793A (en) 1994-02-03
BR9303235A (pt) 1994-03-01
IL106516A0 (en) 1993-11-15
DE69318077D1 (de) 1998-05-28
PL172830B1 (pl) 1997-12-31
FI933391A7 (fi) 1994-02-01
CA2101502A1 (en) 1994-02-01
KR940005636A (ko) 1994-03-22
GR3026699T3 (en) 1998-07-31
UA37181C2 (uk) 2001-05-15
ES2115725T3 (es) 1998-07-01
CN1037683C (zh) 1998-03-11
PH30109A (en) 1996-12-27
CN1089948A (zh) 1994-07-27
NO932745L (no) 1994-02-01
HU219637B (hu) 2001-06-28

Similar Documents

Publication Publication Date Title
EP0581552B1 (en) Triazolylthiomethylthio cephalosporin hyrochloride, its crystalline hydrate and the production of the same
JPH0128036B2 (pl)
US20050245738A1 (en) Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
FI72978C (fi) Foerfarande foer franstaellning av som laekemedel anvaendbara alkyl-(eller alkoxi-)-karbonyloxialkyl-7-/2-(2- aminotiazol-4-yl)-2-hydroxiiminoacetamido/-3-metoximetyl-3-cefem-4- karboxylat.
CA2002596A1 (en) Hydrates of b-lactam antibiotic
JPH0245634B2 (pl)
FI74972B (fi) Foerfarande foer framstaellning av farmaceutiskt vaerdefull 7 -/(z)-2-(2-aminotiazol/-4-yl)-2-oxi- imino-acetamido/-3-cefem-4-karboxylsyra.
US4189479A (en) Cephalosporin esters
EP0547646B1 (en) Crystalline form of a cephalosporin antibiotic
KR0158883B1 (ko) 결정성 세펨산 부가염 및 이의 제조방법
JPH0741484A (ja) セフェム化合物及び抗菌剤
JPS6232194B2 (pl)
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
AU2006300882B2 (en) Crystalline sodium salt of cephalosporin antibiotic
EP0439353B1 (en) Crystalline hydrochloride of new beta-lactam antibiotic and process therefor
CN1315846C (zh) 7 －{ [ ( 5 －氨基 － 1 , 2 , 4 －噻二唑 － 3 －基 ) (氟代甲氧基亚氨基 )乙酰基 ]氨基} － 3 － [ (亚氨基 － 1－哌嗪基甲基 ) －甲基亚肼基 ] －甲基 －3 －头孢烯 － 4 －羧酸的结晶盐酸化物
WO2010020871A2 (en) Crystalline sodium salt of cephalosporin antibiotic
IE47929B1 (en) Substituted imidazolidinyl-3-chloro-3-cephem-4-carboxylic acids
US4497811A (en) 1-Oxadethiacephalosporin compound and antibacterial agent containing the _same
GB2091263A (en) 7-((carboxy-methoximino)-lh-pyrazol-3-yl-acetyl))-amino-3-desacetoxy-3-(l-methyl-lh-tetrazol-5-yl-thio)cepha 10-sporanic acid
US4405618A (en) Thiazolidine derivatives with antibiotic activity
EP0098615B1 (en) 1-oxadethiacephalosporin compound and antibacterial agent containing the same
NO884417L (no) Monohydrat og solvater av et nytt beta-laktam-antibiotikumog fremgangsmaate for fremstilling derav.
SI8510745A8 (sl) Postopek za pripravo soli-hidratov derivatov cefalosporina

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force